SCHEMBL2763031

SCHEMBL2763031

COc1cccc2c1Sc1ccc(N)cc1C2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BLM P54132 1/20 0.43
MAPT P10636 5/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
ALDH1A1 P00352 3/20 0.38
KDM4E B2RXH2 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
NPC1 O15118 1/20 0.38
LMNA P02545 1/20 0.38
HPGD P15428 1/20 0.38
RAB9A P51151 1/20 0.38
ATM Q13315 5/20 0.36
PIK3C3 Q8NEB9 5/20 0.36
PIK3CA P42336 1/20 0.36
PRKDC P78527 1/20 0.36
HTR2A P28223 1/20 0.35
GAA P10253 2/20 0.35
TSHR P16473 1/20 0.35
MAPK1 P28482 1/20 0.35
HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13451292 0.78 BLM (0.46) BLMMAPTMEN1KMT2AALDH1A1
SCHEMBL13113891 0.78 BLM (0.46) BLMMAPTMEN1KMT2AALDH1A1
SCHEMBL3159752 0.78 BLM (0.46) BLMMAPTMEN1KMT2AALDH1A1
SCHEMBL2762743 0.78 HTT (0.43) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL2763156 0.72 CA12 (0.40) MAPTMEN1KMT2AALDH1A1HPGD
SCHEMBL17025412 0.68 BLM (0.51) BLMMAPTMEN1KMT2AALDH1A1
SCHEMBL4936881 0.68 BLM (0.54) BLMMAPTMEN1KMT2AALDH1A1
SCHEMBL28637871 0.66
Thioxanthene SCHEMBL10514224 0.63 MEN1 (0.61) BLMMAPTMEN1KMT2AALDH1A1
SCHEMBL28270304 0.63 MEN1 (0.61) BLMMAPTMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1485377-B9 PYRANONES USEFUL AS ATM INHIBITORS KUDOS PHARM LTD (GB) 2010-10-06 EP disclosed
EP-1485377-B9 PYRANONES USEFUL AS ATM INHIBITORS KUDOS PHARM LTD (GB) 2010-10-06 EP disclosed
EP-2174939-A1 Pyranones useful as ATM inhibitors Kudos Pharmaceuticals Limited (GB) 2010-04-14 EP disclosed
EP-2174939-A1 Pyranones useful as ATM inhibitors Kudos Pharmaceuticals Limited (GB) 2010-04-14 EP disclosed
EP-1485377-B1 PYRANONES USEFUL AS ATM INHIBITORS KUDOS PHARM LTD (GB) 2009-12-09 EP disclosed
EP-1485377-B1 PYRANONES USEFUL AS ATM INHIBITORS KUDOS PHARM LTD (GB) 2009-12-09 EP disclosed
US-7049313-B2 ATM inhibitors KUDOS PHARMACEUTICALS LTD. (GB) 2006-05-23 US disclosed
EP-1485377-A1 PYRANONES USEFUL AS ATM INHIBITORS Kudos Pharmaceuticals Limited (GB) 2004-12-15 EP disclosed
US-20040002492-A1 Induce immunology response; anticancer agents KUDOS PHARMACEUTICALS LTD (GB) 2004-01-01 US disclosed
WO-2003070726-A1 PYRANONES USEFUL AS ATM INHIBITORS KUDOS PHARMACEUTICALS LTD (GB) 2003-08-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002492-A1 Induce immunology response; anticancer agents MYD88, IFNG, HCCS BLM 1183/4885MAPT 4832/4885MEN1 3307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.